GNH USA

Europe — EMA

Igamad

GNH USA supplies Igamad (Human Anti-D Immunoglobulin), a immunoglobulin (anti‑D) for prevention of Rh alloimmunization and treatment of immune

Human Anti-D Immunoglobulin

Request sourcing

1
Pack/s

What is Human Anti-D Immunoglobulin?

Human Anti-D Immunoglobulin, the active ingredient in Igamad, is an Immunoglobulin (anti‑D) presented as an injectable solution for intramuscular use. It is used to prevent Rh alloimmunization in Rh‑negative pregnant women and to treat immune thrombocytopenic purpura. GNH USA supplies Igamad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

What is Human Anti-D Immunoglobulin used for?

Igamad is an anti‑D immunoglobulin used in conditions related to Rh‑D antigen exposure and immune‑mediated platelet destruction. - Prevention of Rh alloimmunization: reduces maternal sensitisation to RhD antigen in Rh‑negative pregnant women. - Treatment of immune thrombocytopenic purpura (ITP): helps raise platelet counts in patients with ITP. - Prevention of hemolytic disease of the newborn: lowers risk of fetal‑neonatal anemia caused by Rh incompatibility.

What are the side effects of Human Anti-D Immunoglobulin?

Adverse reactions may occur following intramuscular administration of Igamad.

Common Side Effects: - Injection site pain or tenderness - Mild fever or chills - Headache - Nausea - Fatigue - Local erythema

Serious or Rare Side Effects: - Anaphylactic reaction - Severe allergic response (urticaria, angioedema) - Hemolysis - Thrombotic events - Renal impairment - Severe hypotension

What precautions apply to Human Anti-D Immunoglobulin?

Use of Igamad requires careful clinical assessment and monitoring. - Rh status verification: confirm patient is Rh‑negative before administration. - Platelet monitoring: observe platelet counts in ITP patients after dosing. - IgA deficiency screening: avoid in individuals with known anti‑IgA antibodies. - Hypersensitivity caution: discontinue if severe allergic reaction occurs. - Cardiovascular caution: monitor patients with underlying heart disease for hemodynamic changes. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Human Anti-D Immunoglobulin interact with?

Igamad may interact with other therapies that affect the immune system or blood components.

Major Interactions (Avoid): - Concurrent administration of other anti‑D immunoglobulins: risk of excessive immune modulation. - Simultaneous infusion of large-volume blood products: potential for circulatory overload.

Moderate Interactions (Monitor Closely): - Live vaccines: may reduce vaccine efficacy, monitor immune response. - Anticoagulants: observe for altered bleeding risk. - Corticosteroids: may affect immunoglobulin clearance, adjust monitoring. - Immunosuppressants: possible reduced therapeutic effect of Igamad.

Frequently asked questions

What is Igamad used for?+
Igamad is a human anti‑D immunoglobulin indicated for preventing Rh alloimmunization in Rh‑negative pregnant women and for treating immune thrombocytopenic purpura (ITP). It works by binding to the RhD antigen on red blood cells, thereby reducing maternal sensitisation and helping to raise platelet counts in ITP patients.
How does Human Anti-D Immunoglobulin work?+
Human Anti-D Immunoglobulin binds to the RhD antigen on red blood cells, forming immune complexes that are cleared by the reticuloendothelial system. This prevents the mother's immune system from developing antibodies against Rh‑positive fetal cells and also modulates immune mechanisms that contribute to platelet destruction in ITP.
What is the usual dose of Igamad?+
The dosage of Igamad is determined by the prescribing clinician based on the specific indication, patient weight, and clinical response. Healthcare professionals calculate the appropriate amount and schedule according to established guidelines and individual patient factors.
Is Igamad safe to use during pregnancy or breastfeeding?+
Igamad is administered to Rh‑negative pregnant women to prevent alloimmunization, a use that is generally considered safe when prescribed by a qualified obstetrician. Data on breastfeeding are limited; clinicians should weigh potential benefits against any unknown risks and advise patients accordingly.
How do I order Igamad from GNH USA?+
To order Igamad, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.
How does Igamad compare with other anti‑D products?+
Igamad is comparable to other human anti‑D immunoglobulins in its mechanism of binding RhD antigen and preventing sensitisation. Differences may lie in manufacturing processes, purity levels, and regulatory approvals. Clinicians should consider product-specific data, availability, and institutional preferences when selecting an anti‑D therapy.
What are the storage requirements for Igamad?+
Igamad must be stored at 2‑8 °C in a refrigerator. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Maintaining the cold chain is essential to preserve product stability and efficacy.
How is Igamad administered?+
Igamad is supplied as an injectable solution for intramuscular injection. The healthcare professional selects an appropriate injection site, typically the deltoid or gluteal muscle, and follows aseptic technique. The exact volume and administration schedule are determined by the prescriber.
What are the most serious risks associated with Igamad?+
Serious risks include anaphylactic or severe allergic reactions, hemolysis, thrombotic events, renal impairment, and severe hypotension. Patients should be monitored closely during and after administration, and any signs of these reactions require immediate medical attention.
Who should not receive Igamad?+
Igamad should be avoided in individuals with known hypersensitivity to human anti‑D immunoglobulin or any of its excipients, and in patients with documented IgA deficiency who have anti‑IgA antibodies. Caution is also advised for patients with severe cardiovascular disease or uncontrolled hypertension.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Human Anti-D Immunoglobulin
Route
Intramuscular Use
Manufacturer
Instituto Grifols, S.A.
Origin
EU

Related products

A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU